{"gene":"ZNF217","run_date":"2026-06-11T09:02:07","timeline":{"discoveries":[{"year":1998,"finding":"ZNF217 encodes Krüppel-like transcription factors (1,062 and 1,108 aa) with eight C2H2 zinc fingers and a proline-rich transcription activation domain, and localizes to the nucleus; it was identified by positional cloning of the 20q13.2 amplicon.","method":"Positional cloning, sequence analysis, expression analysis","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — positional cloning with sequence analysis and expression characterization, single study but multiple methods","pmids":["9671742"],"is_preprint":false},{"year":2001,"finding":"ZNF217 overexpression in finite-lifespan human mammary epithelial cells (HMECs) drives immortalization, allowing cells to overcome senescence and acquire telomerase activity, stable telomere length, and resistance to TGF-β growth inhibition.","method":"Retroviral transduction of ZNF217 into primary HMECs; telomerase activity assays; TGF-β sensitivity assays","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 / Strong — four independent immortalization experiments with functional readouts (telomerase, TGF-β resistance), single lab but replicated internally with multiple orthogonal assays","pmids":["11245413"],"is_preprint":false},{"year":2005,"finding":"ZNF217 localizes predominantly to the nucleus and attenuates apoptotic signals from telomere dysfunction and doxorubicin-induced DNA damage; silencing ZNF217 by siRNA restores doxorubicin sensitivity. ZNF217 also increases Akt phosphorylation, and PI3K/Akt pathway inhibition decreases ZNF217 protein levels.","method":"siRNA knockdown; ZNF217 overexpression; apoptosis assays; immunoblotting for p-Akt; subcellular fractionation/localization","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 2 / Moderate — gain- and loss-of-function with multiple orthogonal readouts (apoptosis, Akt phosphorylation, drug sensitivity) in a single focused study","pmids":["16203743"],"is_preprint":false},{"year":2006,"finding":"ZNF217 is a transcriptional repressor whose purified complex (~6 proteins) contains CoREST, BHC110/LSD1, HDAC2, and CtBP1; the complex possesses histone deacetylase activity and H3K4-specific demethylase activity. ZNF217 binds a specific DNA consensus recognition sequence (CRS) present in the E-cadherin promoter and represses E-cadherin transcription in vivo.","method":"Affinity purification of ZNF217 complex; HDAC and H3K4 demethylase in vitro assays; CAST assay for DNA CRS; ChIP; siRNA knockdown with transient transfection reporter assays","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1 / Strong — complex purification with in vitro enzymatic assays and DNA-binding selection, validated by ChIP and functional reporter assays, multiple orthogonal methods","pmids":["17130829"],"is_preprint":false},{"year":2006,"finding":"ZNF217 contacts CtBP via two distinct motifs: a canonical PXDLS motif and a novel RRT (Arg-Arg-Thr) motif. The crystal structure of CtBP bound to an RRTGAPPAL peptide shows the RRT motif contacts a surface crevice distinct from the PXDLS-binding cleft. Mutations preventing ZNF217–CtBP contact reduce ZNF217-mediated transcriptional repression.","method":"Crystal structure of CtBP–RRT peptide complex; mutagenesis; transcriptional reporter assays","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure with functional mutagenesis validation in transcriptional assays","pmids":["16940172"],"is_preprint":false},{"year":2007,"finding":"Genome-wide ChIP-chip analysis identified thousands of ZNF217 binding sites in tumor cell lines; many promoters co-bound by ZNF217 and CtBP2 are activated upon ZNF217 removal, confirming ZNF217 functions as a transcriptional repressor. ZNF217 targets are enriched in organ development genes, and ZNF217 is downregulated during retinoic acid-induced differentiation of NTera2 cells.","method":"ChIP-chip (chromatin immunoprecipitation with microarray); ZNF217 siRNA knockdown; gene expression profiling","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — genome-wide ChIP-chip with functional follow-up by siRNA knockdown and expression profiling, multiple orthogonal methods","pmids":["17259635"],"is_preprint":false},{"year":2008,"finding":"The p15ink4b tumor suppressor gene is a direct target of the ZNF217/CoREST complex; ZNF217 knockdown in MCF-7 cells dramatically increases p15ink4b expression with increases in H3K4 dimethylation at its promoter. TGF-β stimulation releases ZNF217 from the p15ink4b promoter and allows SMAD2 binding and gene activation.","method":"Genome-wide expression profiling combined with ChIP-DSL; siRNA knockdown; ChIP for histone marks; TGF-β stimulation assays","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — ChIP-DSL genome-wide approach plus targeted siRNA and histone mark analysis with multiple orthogonal methods in single focused study","pmids":["18625718"],"is_preprint":false},{"year":2008,"finding":"ZNF217 overexpression in immortalized ovarian surface epithelial cells (IOSE) transcriptionally activates eEF1A2, and siRNA to eEF1A2 reverses both eEF1A2-driven and ZNF217-driven anchorage independence and apoptosis resistance, placing eEF1A2 downstream of ZNF217 in a neoplastic transformation pathway.","method":"Retroviral ZNF217 overexpression; siRNA knockdown of eEF1A2; array CGH; Affymetrix expression analysis; anchorage independence and apoptosis assays","journal":"International journal of cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — epistasis established by siRNA rescue experiments with multiple phenotypic readouts, single lab","pmids":["18661515"],"is_preprint":false},{"year":2009,"finding":"A ZNF217 nuclear complex purified by affinity chromatography contains Jarid1b/Plu-1, G9a, LSD1, CoREST, and CtBP1 (confirmed by co-IP); the complex exhibits H3K4me3 demethylase activity (co-fractionating with Jarid1b), H3K9 methyltransferase activity (via G9a), and H3K27 methylation activity; EZH2 is an additional ZNF217 binding partner confirmed by co-IP.","method":"Affinity chromatography; mass spectrometry; co-immunoprecipitation; in vitro histone methylation and demethylation assays; anion-exchange chromatography fractionation","journal":"Epigenetics","confidence":"High","confidence_rationale":"Tier 1 / Moderate — affinity purification plus mass spectrometry, confirmed by co-IP, with in vitro enzymatic activity assays; single lab but multiple orthogonal methods","pmids":["19242095"],"is_preprint":false},{"year":2010,"finding":"ZNF217 activates ErbB3 expression in breast cancer cells; ZNF217 recruitment to the ErbB3 promoter is CtBP1/2-independent, and ZNF217 and CtBP1/2 have opposing roles at the ErbB3 promoter. ErbB3 upregulation is one mechanism by which ZNF217 augments PI3K/Akt signaling.","method":"Ectopic ZNF217 expression; siRNA knockdown; ChIP; correlation analysis across 50 breast cancer cell lines and 15 primary tumors","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP and gain/loss-of-function with expression correlation, single lab, multiple methods","pmids":["20661224"],"is_preprint":false},{"year":2010,"finding":"ZNF217 overexpression in MDA-MB-231 cells confers resistance to paclitaxel through deregulation of Bcl-2 family protein balance in the intrinsic apoptotic pathway; ZNF217 overexpression also increases Aurora-A protein expression, and Aurora-A kinase inhibition reverses paclitaxel resistance.","method":"Stable ZNF217 overexpression; siRNA knockdown; apoptosis assays; Bcl-2 family immunoblotting; Aurora-A inhibitor treatment; xenograft assays","journal":"Molecular cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain- and loss-of-function with mechanistic (Bcl-2 family, Aurora-A) and pharmacological rescue, single lab","pmids":["21059223"],"is_preprint":false},{"year":2011,"finding":"ZNF217 DNA-binding activity is mediated by a two-finger unit (zinc fingers 6 and 7); NMR analysis and mutagenesis define the DNA binding surface, and the E-cadherin promoter site is a suboptimal binding site. Multi-finger proteins with two-finger units represent a distinct subclass of DNA recognition motif.","method":"NMR analysis; fluorescence anisotropy titrations; mutagenesis; sequence analysis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — NMR structure plus mutagenesis and biophysical binding assays in a single rigorous study","pmids":["21908891"],"is_preprint":false},{"year":2012,"finding":"The ZNF217/CoREST complex occupies the p15ink4b promoter together with DNMT3A; TGF-β treatment triggers active DNA demethylation by loss of ZNF217/CoREST/DNMT3A and recruitment of SMAD2/3, CBP, and TDG glycosylase. ZNF217 overexpression prevents TGF-β-dependent demethylation and p15ink4b expression by blocking SMAD2/3 and TDG recruitment; 5mC is converted to 5hmC prior to p15ink4b activation.","method":"ChIP and ChIP-seq; DNA immunoprecipitation for 5mC and 5hmC; TDG/MBD4 siRNA knockdown; ZNF217 overexpression; TGF-β stimulation","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — ChIP-seq plus functional demethylation assays, siRNA epistasis, and 5mC/5hmC IP in a rigorous multi-method study","pmids":["22560925"],"is_preprint":false},{"year":2013,"finding":"Crystal structure of a ZNF217 two-zinc-finger–DNA complex reveals that the side-chain interaction pattern differs substantially from the canonical ZF model and identifies two methyl-π interactions (tyrosine–thymine methyl) not previously described in classical ZF–DNA complexes.","method":"X-ray crystal structure determination of ZNF217 ZF6-7–DNA complex","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — crystal structure with detailed structural analysis, single study but Tier 1 method","pmids":["23436653"],"is_preprint":false},{"year":2014,"finding":"ZNF217 and ERα proteins physically interact via the ERα hinge domain and the ZNF217 C-terminal domain (confirmed by co-IP in breast cancer cells and primary tumor samples); ZNF217 enhances ERα recruitment to estrogen response elements and ERα-dependent transcription of GREB1.","method":"Co-immunoprecipitation in cell lines and primary tumor samples; domain-mapping experiments; ChIP; transcriptional reporter assays","journal":"Molecular oncology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal co-IP in cells and tumors with ChIP and reporter assays, single lab, multiple orthogonal methods","pmids":["24973012"],"is_preprint":false},{"year":2014,"finding":"Genome-wide ChIP-seq in MCF7 cells shows ZNF217 binding sites are enriched at distal regulatory regions marked by H3K27ac and H3K4me1, clustering with FOXA1, GATA3, and ERα binding sites; ERα co-precipitates ZNF217 and CtBP2 from nuclear extracts; ZNF217 depletion alters expression of genes co-bound by ZNF217 and ERα.","method":"ChIP-seq; co-immunoprecipitation; transcriptome profiling after ZNF217 siRNA depletion; bioinformatic motif enrichment analysis","journal":"BMC genomics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP-seq with co-IP and transcriptome profiling, single lab, multiple methods","pmids":["24962896"],"is_preprint":false},{"year":2016,"finding":"ZNF217 inhibits m6A methylation of NANOG and KLF4 mRNAs under hypoxia in breast cancer cells, promoting BCSC specification; this ZNF217-dependent inhibition of m6A methylation is HIF-dependent and occurs independently of or in parallel with ALKBH5-mediated demethylation.","method":"ZNF217 knockdown; m6A quantification; HIF knockdown; pluripotency factor expression assays; in vivo metastasis assay","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — m6A quantification with siRNA epistasis (ZNF217, HIF knockdown) and in vivo validation, single lab","pmids":["27590511"],"is_preprint":false},{"year":2016,"finding":"ZNF217 positively regulates E2 (estradiol) synthesis in granulosa cells by promoting CREB and thereby CYP19A1 (aromatase) expression; ZNF217 also negatively regulates TSP-1 expression, modulating vascular permeability through downstream claudin-1 and NO.","method":"In vitro KGN cell overexpression and knockdown of ZNF217; E2 assays; RT-qPCR for CYP19A1, CREB, TSP-1; vascular cell functional assays","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain- and loss-of-function in cell lines with multiple downstream readouts, single lab","pmids":["28607476"],"is_preprint":false},{"year":2016,"finding":"ZNF217 interacts with MDM2; when co-expressed, ZNF217 and MDM2 form a complex and ZNF217 reduces acetylated p53 levels and suppresses p53-dependent p21 promoter activation, in part through recruitment of HDAC1.","method":"MDM2 affinity chromatography; mass spectrometry identification of ZNF217; co-expression in cancer cells; p53 acetylation immunoblotting; p21 promoter reporter assays","journal":"Biochemistry and cell biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — affinity chromatography/MS identification, co-expression functional assays, single lab, multiple methods","pmids":["27792410"],"is_preprint":false},{"year":2016,"finding":"ZNF217 interacts with EZH2 to facilitate H3K27me3 at the ferroportin (FPN) promoter, repressing FPN transcription and retaining intracellular iron; MAZ transcription factor activates ZNF217 transcription and this axis regulates iron metabolism in prostate cancer cells.","method":"Co-immunoprecipitation of ZNF217 and EZH2; ChIP for H3K27me3 at FPN promoter; siRNA knockdown; overexpression assays; iron and cell growth assays","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP plus ChIP with functional iron metabolism readouts, single lab","pmids":["27768596"],"is_preprint":false},{"year":2017,"finding":"ZNF217 overexpression in breast cancer cells activates the BMP signaling pathway, contributing to bone metastasis; BMP pathway inhibition (Noggin, LDN-193189) rescues ZNF217-dependent cell migration, invasion, and chemotaxis toward bone environment. ZNF217 increases metastatic growth rate and osteolytic lesions in vivo.","method":"Stable ZNF217 transfection; in vitro migration/invasion/chemotaxis assays; BMP inhibitor treatment; in vivo multimodal imaging in mouse models","journal":"The Journal of pathology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological and genetic epistasis with in vivo imaging, single lab, multiple methods","pmids":["28207159"],"is_preprint":false},{"year":2019,"finding":"ZNF217 physically interacts with LSD1 in vivo and in vitro; ZNF217 knockdown increases H3K4me2 at the CDH1 (E-cadherin) promoter, indicating ZNF217 recruits LSD1 to epigenetically repress CDH1 transcription in hepatocellular carcinoma cells.","method":"Co-immunoprecipitation in vivo and in vitro; ChIP for H3K4me2; siRNA knockdown of ZNF217; expression analysis","journal":"Experimental cell research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP plus ChIP with siRNA functional follow-up, single lab, multiple orthogonal methods","pmids":["30898548"],"is_preprint":false},{"year":2020,"finding":"ZNF217 mediates matrix stiffness- and collagen density-induced increases in Akt activity and mammary epithelial cell proliferation; ZNF217 is regulated by miR-203, which is repressed by matrix stiffness. In a mouse mammographic density model, reduced miR-203 correlates with higher Zfp217 (murine homolog) and elevated Akt activity.","method":"ZNF217 manipulation in culture; miR-203 profiling; Akt activity assays; mouse mammographic density model; quantitative proteomics and mechanical measurements of breast stroma","journal":"The Journal of clinical investigation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple in vitro and in vivo methods with mechanistic epistasis (miR-203/ZNF217/Akt), single lab","pmids":["32721948"],"is_preprint":false},{"year":2020,"finding":"ZNF217 forced expression in PCOS theca cells reduces androgen (DHEA) production, CYP17A1 mRNA, and DENND1A.V2 mRNA, while increasing miR-130b-3p levels; conversely, ZNF217 knockdown in normal theca cells increases DENND1A.V2 and CYP17A1 mRNA.","method":"ZNF217 overexpression in PCOS theca cells; shRNA lentiviral knockdown in normal theca cells; RT-qPCR for CYP17A1, DENND1A.V2, miR-130b-3p; androgen production assays","journal":"Journal of the Endocrine Society","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain- and loss-of-function with multiple downstream endocrine readouts, single lab","pmids":["35668995"],"is_preprint":false},{"year":2022,"finding":"ZNF217 upregulates NANOG expression by reducing N6-methyladenosine (m6A) levels via interaction with METTL3; co-immunoprecipitation and methylated-RNA binding protein IP and PAR-CLIP assays confirmed ZNF217 interferes with METTL3-dependent m6A methylation of NANOG mRNA, promoting EMT in breast cancer.","method":"Co-immunoprecipitation; methylated-RNA immunoprecipitation; PAR-CLIP; dual-luciferase assay for miR-135/ZNF217 interaction; ZNF217 knockdown; xenograft assays","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP and MeRIP assays demonstrating m6A regulation mechanism, single lab, multiple orthogonal methods","pmids":["35121826"],"is_preprint":false},{"year":2023,"finding":"ZNF217 acts within a histone modifier complex containing LSD1, CoREST, and HDAC (confirmed by mass spectrometry), and knockout of ZNF217 in PMBCL cells changes chromatin accessibility at binding motifs for lymphoma-associated transcription factors, interfering with H3K4 methylation and H3K27 acetylation and altering expression of interferon-responsive genes.","method":"Targeted sequencing; ZNF217 knockout; mass spectrometry; gene expression profiling; ATAC-seq (chromatin accessibility); histone modification analysis","journal":"Leukemia","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — MS-confirmed complex plus chromatin accessibility (ATAC-seq) and histone modification analysis with KO functional follow-up, single lab, multiple orthogonal methods","pmids":["37648814"],"is_preprint":false},{"year":2023,"finding":"ZNF217 activates Notch1 transcription (confirmed by dual-luciferase reporter assay) to sustain cancer stem cell self-renewal and colorectal CSC marker expression; Notch1 knockdown rescues ZNF217-overexpression-driven stem cell properties.","method":"Dual-luciferase reporter assay; ZNF217 overexpression; Notch1 knockdown; CSC marker and sphere formation assays; in vivo xenograft","journal":"The Journal of nutritional biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reporter assay establishing direct transcriptional activation with epistasis by Notch1 KD, single lab","pmids":["38134973"],"is_preprint":false},{"year":2023,"finding":"Dimethyl fumarate (DMF) covalently modifies ZNF217 at cysteine residues (identified by cysteine-directed proteomics and confirmed with a DMF-chemical probe), inhibiting ZNF217 transcriptional activity on target genes and suppressing ZNF217-driven cancer phenotypes.","method":"Cysteine-directed activity-based proteomics; DMF-chemical probe confirmation; ZNF217 target gene expression analysis; gain/loss-of-function of ZNF217 combined with DMF treatment; xenograft assay","journal":"Breast cancer research and treatment","confidence":"Medium","confidence_rationale":"Tier 1-2 / Moderate — chemical proteomics identification confirmed by probe, with functional epistasis; single lab but two independent chemical methods","pmids":["37477798"],"is_preprint":false},{"year":2024,"finding":"ZNF217 transcriptionally activates GRHL3 expression in thyroid cancer cells; GRHL3 in turn activates SLC22A31 transcription, forming a ZNF217/GRHL3/SLC22A31 axis promoting thyroid cancer cell malignancy; rescue overexpression of GRHL3 or SLC22A31 abrogates the effects of ZNF217 knockdown.","method":"Lentiviral knockdown of ZNF217, GRHL3, SLC22A31; RT-qPCR; bioinformatics differential expression; functional rescue assays","journal":"Molecular biotechnology","confidence":"Low","confidence_rationale":"Tier 3 / Weak — epistasis by siRNA/shRNA rescue without direct promoter binding confirmation for ZNF217→GRHL3, single lab, single method type","pmids":["39354204"],"is_preprint":false},{"year":2025,"finding":"ZNF217 is essential for B-ALL cell survival driven by MLL rearrangement or BCR-ABL; ZNF217 exerts oncogenic activity through both CoREST-dependent and CoREST-independent mechanisms; FOS is a direct downstream transcriptional target repressed by ZNF217 in a CoREST-independent manner (identified by integrated RNA-seq and CUT&RUN-seq).","method":"CRISPR-Cas9 screen; gain/loss-of-function assays; RNA-seq; CUT&RUN-seq; xenograft and PDX models","journal":"Theranostics","confidence":"High","confidence_rationale":"Tier 2 / Moderate — CRISPR screen plus CUT&RUN-seq and RNA-seq mechanistic dissection with PDX model validation, single lab but multiple orthogonal genomic and functional methods","pmids":["40093906"],"is_preprint":false},{"year":2025,"finding":"ZNF217 and LSD1 co-occupy the EBV immediate-early gene BZLF1 promoter and oriLyt enhancer regions; knockout of ZNF217 or LSD1, or CoREST triggers EBV lytic reactivation, and LSD1 depletion increases H3K4 methylation (but not H3K9me) at BZLF1 and oriLyt, inducing their long-range looping. ZNF217 thus functions as a restriction factor for EBV lytic reactivation within the LSD1/ZNF217/CoREST complex.","method":"Genome-wide CRISPR-Cas9 screen; ZNF217/LSD1/CoREST knockout; ChIP for H3K4me; 3D chromatin (looping) analysis; EBV reactivation assays; LSD1 small molecule antagonist; ganciclovir cytotoxicity assays; murine xenograft","journal":"Research square (preprint)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — CRISPR KO with ChIP and 3D chromatin assays in multiple cancer models; preprint with multiple methods but not yet peer-reviewed","pmids":["39877093"],"is_preprint":true},{"year":2025,"finding":"ZNF217 promotes AML cell proliferation by directly activating MYB transcription; ZNF217 is part of the AML core transcriptional regulatory circuit (CRC) with ELF1, MEF2D, RUNX2, and FOXP1, sustaining super-enhancer activity through mutual auto-regulation loops. ZNF217 binding to MYB regulatory regions was confirmed by CUT&Tag.","method":"ChIP-seq analysis; CUT&Tag; shRNA knockdown; luciferase reporter assays; RNA-seq; in vitro and in vivo proliferation/viability assays","journal":"International journal of biological sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — CUT&Tag chromatin occupancy plus reporter assays and RNA-seq identifying MYB as direct target, single lab, multiple methods","pmids":["40083704"],"is_preprint":false}],"current_model":"ZNF217 is a nuclear Krüppel-like C2H2 zinc-finger transcription factor that assembles a multi-subunit repressor complex containing LSD1/BHC110, CoREST, HDAC1/2, CtBP1/2, Jarid1b, G9a, and EZH2 to impose histone H3K4 demethylation, H3K9/H3K27 methylation, and histone deacetylation at target promoters; it binds DNA through a two-finger unit (ZF6–7) via a non-canonical interaction mode, represses tumor suppressors including p15ink4b, E-cadherin, and ferroportin, and also activates specific genes (ErbB3, Aurora-A, Notch1, MYB) in context-dependent, sometimes CtBP-independent manners; it further inhibits m6A methylation of pluripotency factor mRNAs by interfering with METTL3, interacts with ERα and MDM2 to modulate estrogen-responsive and p53-dependent transcription, and sustains cell survival partly through Akt/PI3K pathway activation, collectively driving immortalization, chemoresistance, EMT, metastasis, and cancer stem cell maintenance."},"narrative":{"mechanistic_narrative":"ZNF217 is a Krüppel-like C2H2 zinc-finger transcription factor that nucleates a chromatin-modifying repressor complex to silence developmental and tumor-suppressor genes while driving cellular immortalization and oncogenic transformation [PMID:9671742, PMID:11245413, PMID:17130829]. It recognizes DNA through a non-canonical two-finger unit (zinc fingers 6 and 7) whose side-chain contacts and tyrosine–thymine methyl-π interactions depart from the classical zinc-finger recognition mode [PMID:21908891, PMID:23436653]. Once bound, ZNF217 assembles a multi-subunit corepressor complex containing CoREST, LSD1/BHC110, HDAC1/2, and CtBP1/2 — engaging CtBP via both a canonical PXDLS motif and a novel RRT motif — and recruits additional histone modifiers Jarid1b, G9a, and EZH2 to impose H3K4 demethylation, H3K9/H3K27 methylation, and histone deacetylation at target promoters [PMID:17130829, PMID:16940172, PMID:19242095, PMID:30898548, PMID:37648814]. Through this complex ZNF217 directly represses tumor suppressors including p15ink4b, E-cadherin (CDH1), and ferroportin, and at the p15ink4b promoter it cooperates with DNMT3A and antagonizes TGF-β-driven SMAD2/3 recruitment and active DNA demethylation [PMID:17130829, PMID:18625718, PMID:22560925, PMID:27768596, PMID:30898548]. Beyond repression, ZNF217 activates context-specific targets — ErbB3, Aurora-A, Notch1, MYB, and FOS — sometimes in a CtBP- or CoREST-independent manner, augmenting PI3K/Akt signaling, conferring chemoresistance, and sustaining cancer stem-cell self-renewal [PMID:16203743, PMID:20661224, PMID:21059223, PMID:38134973, PMID:40093906, PMID:40083704]. ZNF217 additionally interacts with ERα to enhance estrogen-responsive transcription and with MDM2 to suppress p53-dependent transactivation, and it inhibits METTL3-dependent m6A methylation of pluripotency factor mRNAs (NANOG, KLF4) to promote EMT and breast cancer stem-cell specification [PMID:24973012, PMID:24962896, PMID:27792410, PMID:27590511, PMID:35121826]. Collectively these activities drive immortalization, EMT, metastasis, and therapy resistance across multiple cancer types [PMID:11245413, PMID:28207159, PMID:40093906].","teleology":[{"year":1998,"claim":"Establishing ZNF217's molecular identity was the first step: it answered whether the recurrently amplified 20q13.2 locus encoded a defined regulatory protein.","evidence":"Positional cloning and sequence/expression analysis of the 20q13.2 amplicon","pmids":["9671742"],"confidence":"Medium","gaps":["No DNA targets or interacting partners identified","Activation vs repression function undefined"]},{"year":2001,"claim":"Demonstrated that ZNF217 is functionally oncogenic, not merely amplified, by showing it immortalizes primary mammary epithelial cells.","evidence":"Retroviral ZNF217 transduction of HMECs with telomerase and TGF-β resistance readouts","pmids":["11245413"],"confidence":"High","gaps":["Transcriptional targets driving immortalization unknown","Mechanism of TGF-β resistance unresolved"]},{"year":2005,"claim":"Linked ZNF217 to survival signaling, showing it attenuates DNA-damage apoptosis and engages the PI3K/Akt axis, explaining a chemoresistance mechanism.","evidence":"siRNA knockdown and overexpression with apoptosis assays and p-Akt immunoblotting","pmids":["16203743"],"confidence":"High","gaps":["Direct mediators between ZNF217 and Akt not identified","Reciprocal regulation of ZNF217 by Akt mechanistically unclear"]},{"year":2006,"claim":"Defined ZNF217 as a sequence-specific corepressor by purifying its CoREST/LSD1/HDAC2/CtBP1 complex with H3K4 demethylase and deacetylase activity and identifying its DNA consensus, and resolved how it contacts CtBP.","evidence":"Affinity purification, in vitro enzymatic assays, CAST DNA selection, ChIP; plus CtBP–RRT peptide crystal structure with mutagenesis","pmids":["17130829","16940172"],"confidence":"High","gaps":["Full target gene repertoire unknown","Structural basis of DNA recognition not yet determined"]},{"year":2007,"claim":"Established the genome-wide scope of ZNF217 repression, showing it occupies thousands of developmental-gene promoters with CtBP2 and is downregulated during differentiation.","evidence":"ChIP-chip with siRNA knockdown and expression profiling in tumor lines and NTera2 cells","pmids":["17259635"],"confidence":"High","gaps":["Direct vs indirect targets not all distinguished","Mechanism linking binding to activation upon removal unclear"]},{"year":2008,"claim":"Connected ZNF217 to growth control by identifying p15ink4b as a direct CoREST-complex target whose TGF-β activation requires ZNF217 release, and placed eEF1A2 downstream in transformation.","evidence":"ChIP-DSL, histone-mark ChIP, TGF-β stimulation, and siRNA epistasis with eEF1A2","pmids":["18625718","18661515"],"confidence":"High","gaps":["How TGF-β triggers ZNF217 eviction not defined","eEF1A2 regulation mechanism (direct/indirect) unclear"]},{"year":2009,"claim":"Expanded the corepressor complex to include Jarid1b, G9a, and EZH2, establishing that ZNF217 coordinates multiple histone-modifying activities (H3K4 demethylation, H3K9/H3K27 methylation).","evidence":"Affinity chromatography, mass spectrometry, co-IP, and in vitro histone methylation/demethylation assays","pmids":["19242095"],"confidence":"High","gaps":["Stoichiometry and assembly order of subunits unknown","Whether all activities act at the same loci unresolved"]},{"year":2010,"claim":"Showed ZNF217 also functions as a transcriptional activator at specific loci, activating ErbB3 (CtBP-independent) and Aurora-A to drive Akt signaling and paclitaxel resistance.","evidence":"ChIP, gain/loss-of-function, Bcl-2 family immunoblotting, Aurora-A inhibition, and xenografts","pmids":["20661224","21059223"],"confidence":"Medium","gaps":["Molecular switch between repression and activation unknown","Direct vs indirect activation of Aurora-A unclear"]},{"year":2011,"claim":"Resolved the DNA-recognition mechanism, defining a two-finger (ZF6-7) DNA-binding unit and a suboptimal E-cadherin site, establishing ZNF217 as a distinct recognition subclass.","evidence":"NMR analysis, fluorescence anisotropy, and mutagenesis","pmids":["21908891"],"confidence":"High","gaps":["Genome-wide consensus relationship to ZF6-7 specificity incomplete","Role of remaining zinc fingers undefined"]},{"year":2012,"claim":"Detailed the epigenetic mechanism at p15ink4b, showing the ZNF217/CoREST/DNMT3A complex blocks TGF-β-induced active DNA demethylation by preventing SMAD2/3 and TDG recruitment.","evidence":"ChIP-seq, 5mC/5hmC DNA-IP, TDG/MBD4 siRNA, and TGF-β stimulation","pmids":["22560925"],"confidence":"High","gaps":["Generality of DNMT3A coupling beyond p15ink4b unknown","Signal triggering complex displacement not fully defined"]},{"year":2013,"claim":"Provided atomic detail of ZNF217–DNA contacts, revealing non-canonical methyl-π (tyrosine–thymine) interactions absent from classical zinc-finger complexes.","evidence":"X-ray crystal structure of ZF6-7–DNA complex","pmids":["23436653"],"confidence":"High","gaps":["Structure of full-length protein on chromatin unknown","Link between recognition mode and target selection unresolved"]},{"year":2014,"claim":"Integrated ZNF217 into estrogen signaling, showing direct ERα interaction and co-occupancy with FOXA1/GATA3/ERα at distal enhancers regulating estrogen-responsive genes.","evidence":"Co-IP in cells/tumors, domain mapping, ChIP-seq, and transcriptome profiling after depletion","pmids":["24973012","24962896"],"confidence":"Medium","gaps":["Whether ERα coactivation is corepressor-complex-dependent unclear","Single-lab co-IP for ERα–ZNF217 interaction"]},{"year":2016,"claim":"Broadened ZNF217's regulatory range to RNA m6A, p53, and iron metabolism — inhibiting m6A of NANOG/KLF4 under hypoxia, interacting with MDM2 to suppress p53, and partnering with EZH2 to repress ferroportin.","evidence":"m6A quantification with HIF knockdown; MDM2 affinity-MS and p53/p21 assays; EZH2 co-IP and ferroportin ChIP","pmids":["27590511","27792410","27768596","28607476"],"confidence":"Medium","gaps":["Direct vs indirect interference with m6A machinery undefined at this stage","Physiological balance between these distinct activities unknown"]},{"year":2019,"claim":"Confirmed in hepatocellular carcinoma that ZNF217 recruits LSD1 to the CDH1 promoter to enforce E-cadherin silencing via H3K4me2 removal.","evidence":"Co-IP in vivo/in vitro, H3K4me2 ChIP, and siRNA knockdown","pmids":["30898548"],"confidence":"Medium","gaps":["Cell-type generality of LSD1 recruitment to CDH1 unclear","Direct ZNF217 binding to CDH1 promoter in this system not structurally validated"]},{"year":2020,"claim":"Linked ZNF217 to mechanotransduction and metastatic niche signaling — matrix stiffness represses miR-203 to elevate ZNF217 and Akt activity, while ZNF217 activates BMP signaling to promote bone metastasis.","evidence":"miR-203 profiling, Akt assays, mouse mammographic density model; BMP inhibitor rescue and in vivo imaging","pmids":["32721948","28207159"],"confidence":"Medium","gaps":["Direct ZNF217 targets in BMP/mechanotransduction pathways not mapped","Single-lab in vivo findings"]},{"year":2022,"claim":"Mechanistically resolved the m6A connection, showing ZNF217 physically interacts with METTL3 to block m6A methylation of NANOG mRNA and promote EMT.","evidence":"Co-IP, MeRIP, PAR-CLIP, dual-luciferase, knockdown, and xenografts","pmids":["35121826"],"confidence":"Medium","gaps":["Whether ZNF217 directly inhibits METTL3 catalysis or sequesters it unclear","Breadth of m6A-regulated transcripts undefined"]},{"year":2023,"claim":"Extended ZNF217's repressor function to chromatin accessibility in lymphoma and EBV restriction, and uncovered druggability through covalent cysteine modification by dimethyl fumarate.","evidence":"ATAC-seq and MS-confirmed complex in PMBCL; CRISPR-KO ChIP and 3D chromatin in EBV (preprint); cysteine-directed proteomics with DMF probe","pmids":["37648814","37477798","39877093"],"confidence":"High","gaps":["EBV findings from preprint not peer-reviewed","DMF target selectivity in cells not fully defined"]},{"year":2023,"claim":"Established ZNF217 as a transcriptional activator of Notch1 sustaining colorectal cancer stem-cell self-renewal.","evidence":"Dual-luciferase reporter, overexpression, Notch1 knockdown rescue, and sphere/xenograft assays","pmids":["38134973"],"confidence":"Medium","gaps":["Direct promoter occupancy at Notch1 not confirmed by ChIP","Relationship to corepressor complex unclear"]},{"year":2024,"claim":"Proposed a ZNF217/GRHL3/SLC22A31 transcriptional axis driving thyroid cancer malignancy.","evidence":"Lentiviral knockdown and functional rescue without direct promoter-binding confirmation","pmids":["39354204"],"confidence":"Low","gaps":["No direct ZNF217 binding to GRHL3 promoter demonstrated","Single-lab, single-method-type epistasis"]},{"year":2025,"claim":"Defined ZNF217 as essential in leukemia, dissecting CoREST-dependent and -independent oncogenic outputs (FOS repression, MYB activation within a core transcriptional circuit).","evidence":"CRISPR screen, RNA-seq, CUT&RUN/CUT&Tag, reporter assays, and PDX models in B-ALL and AML","pmids":["40093906","40083704"],"confidence":"High","gaps":["Mechanistic basis of CoREST-independent activity unresolved","How a corepressor activates MYB/super-enhancers structurally unclear"]},{"year":null,"claim":"It remains unresolved how ZNF217 switches between corepressor and coactivator functions at different loci and how its CoREST-independent oncogenic activities are mechanistically executed.","evidence":"No single study in the timeline reconciles the activation/repression duality at the molecular level","pmids":[],"confidence":"Medium","gaps":["No structural or biochemical model for context-dependent activation","Determinants of CoREST-dependent vs -independent function unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[3,11,13]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[3,5,6,26,29,31]},{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[3,8]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[4,18,24]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[0,2,8]},{"term_id":"GO:0000228","term_label":"nuclear chromosome","supporting_discovery_ids":[3,6,12,25]}],"pathway":[{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[3,8,12,25]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[5,6,26,29,31]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[1,20,29]},{"term_id":"R-HSA-8953854","term_label":"Metabolism of RNA","supporting_discovery_ids":[16,24]}],"complexes":["ZNF217/CoREST/LSD1/HDAC/CtBP corepressor complex"],"partners":["CTBP1","LSD1","COREST","EZH2","ESR1","MDM2","METTL3","HDAC1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"O75362","full_name":"Zinc finger protein 217","aliases":[],"length_aa":1048,"mass_kda":115.3,"function":"Binds to the promoters of target genes and functions as repressor. Promotes cell proliferation and antagonizes cell death. Promotes phosphorylation of AKT1 at 'Ser-473'","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/O75362/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ZNF217","classification":"Not Classified","n_dependent_lines":534,"n_total_lines":1208,"dependency_fraction":0.4420529801324503},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"CTBP1","stoichiometry":0.2},{"gene":"CTBP2","stoichiometry":0.2},{"gene":"HDAC1","stoichiometry":0.2},{"gene":"HDAC2","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/ZNF217","total_profiled":1310},"omim":[{"mim_id":"603072","title":"AURORA KINASE A; AURKA","url":"https://www.omim.org/entry/603072"},{"mim_id":"602968","title":"BRAIN-ENRICHED MYELIN-ASSOCIATED PROTEIN 1; BCAS1","url":"https://www.omim.org/entry/602968"},{"mim_id":"602967","title":"ZINC FINGER PROTEIN 217; ZNF217","url":"https://www.omim.org/entry/602967"},{"mim_id":"602619","title":"C-TERMINAL-BINDING PROTEIN 2; CTBP2","url":"https://www.omim.org/entry/602619"},{"mim_id":"602618","title":"C-TERMINAL-BINDING PROTEIN 1; CTBP1","url":"https://www.omim.org/entry/602618"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Enhanced","locations":[{"location":"Nuclear speckles","reliability":"Enhanced"},{"location":"Mitochondria","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in many","driving_tissues":[],"url":"https://www.proteinatlas.org/search/ZNF217"},"hgnc":{"alias_symbol":["ZABC1"],"prev_symbol":[]},"alphafold":{"accession":"O75362","domains":[{"cath_id":"3.30.160.60","chopping":"472-526","consensus_level":"medium","plddt":90.1051,"start":472,"end":526},{"cath_id":"3.30.160","chopping":"66-95","consensus_level":"medium","plddt":75.5957,"start":66,"end":95},{"cath_id":"3.30.160","chopping":"709-736","consensus_level":"medium","plddt":89.2529,"start":709,"end":736}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/O75362","model_url":"https://alphafold.ebi.ac.uk/files/AF-O75362-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-O75362-F1-predicted_aligned_error_v6.png","plddt_mean":49.31},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ZNF217","jax_strain_url":"https://www.jax.org/strain/search?query=ZNF217"},"sequence":{"accession":"O75362","fasta_url":"https://rest.uniprot.org/uniprotkb/O75362.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/O75362/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/O75362"}},"corpus_meta":[{"pmid":"9671742","id":"PMC_9671742","title":"Positional cloning of ZNF217 and NABC1: genes amplified at 20q13.2 and overexpressed in breast carcinoma.","date":"1998","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/9671742","citation_count":274,"is_preprint":false},{"pmid":"27590511","id":"PMC_27590511","title":"Hypoxia-inducible factors regulate pluripotency factor expression by ZNF217- and ALKBH5-mediated modulation of RNA methylation in breast cancer cells.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27590511","citation_count":225,"is_preprint":false},{"pmid":"11245413","id":"PMC_11245413","title":"The ZNF217 gene amplified in breast cancers promotes immortalization of human mammary epithelial cells.","date":"2001","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/11245413","citation_count":117,"is_preprint":false},{"pmid":"32721948","id":"PMC_32721948","title":"Stiff stroma increases breast cancer risk by inducing the oncogene ZNF217.","date":"2020","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/32721948","citation_count":101,"is_preprint":false},{"pmid":"17130829","id":"PMC_17130829","title":"Biochemical characterization of the zinc-finger protein 217 transcriptional repressor complex: identification of a ZNF217 consensus recognition sequence.","date":"2006","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/17130829","citation_count":93,"is_preprint":false},{"pmid":"22560925","id":"PMC_22560925","title":"TGF-β-dependent active demethylation and expression of the p15ink4b tumor suppressor are impaired by the ZNF217/CoREST complex.","date":"2012","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/22560925","citation_count":89,"is_preprint":false},{"pmid":"24336158","id":"PMC_24336158","title":"Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations and ZNF217 amplification in ovarian clear cell carcinoma.","date":"2013","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/24336158","citation_count":78,"is_preprint":false},{"pmid":"16940172","id":"PMC_16940172","title":"Specific recognition of ZNF217 and other zinc finger proteins at a surface groove of C-terminal binding proteins.","date":"2006","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/16940172","citation_count":75,"is_preprint":false},{"pmid":"17259635","id":"PMC_17259635","title":"Identification of genes directly regulated by the oncogene ZNF217 using chromatin immunoprecipitation (ChIP)-chip assays.","date":"2007","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17259635","citation_count":73,"is_preprint":false},{"pmid":"19242095","id":"PMC_19242095","title":"The ZNF217 oncogene is a candidate organizer of repressive histone modifiers.","date":"2009","source":"Epigenetics","url":"https://pubmed.ncbi.nlm.nih.gov/19242095","citation_count":69,"is_preprint":false},{"pmid":"27090737","id":"PMC_27090737","title":"Knockdown of lncRNA-ATB suppresses autocrine secretion of TGF-β2 by targeting ZNF217 via miR-200c in keloid fibroblasts.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/27090737","citation_count":67,"is_preprint":false},{"pmid":"17572303","id":"PMC_17572303","title":"Amplification of zinc finger gene 217 (ZNF217) and cancer: when good fingers go bad.","date":"2007","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/17572303","citation_count":65,"is_preprint":false},{"pmid":"22815235","id":"PMC_22815235","title":"Identification of ZNF217, hnRNP-K, VEGF-A and IPO7 as targets for microRNAs that are downregulated in prostate carcinoma.","date":"2012","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/22815235","citation_count":65,"is_preprint":false},{"pmid":"16203743","id":"PMC_16203743","title":"ZNF217 suppresses cell death associated with chemotherapy and telomere dysfunction.","date":"2005","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/16203743","citation_count":61,"is_preprint":false},{"pmid":"20661224","id":"PMC_20661224","title":"ZNF217, a candidate breast cancer oncogene amplified at 20q13, regulates expression of the ErbB3 receptor tyrosine kinase in breast cancer cells.","date":"2010","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/20661224","citation_count":56,"is_preprint":false},{"pmid":"32741808","id":"PMC_32741808","title":"lncRNA SNHG1 Knockdown Alleviates Amyloid-β-Induced Neuronal Injury by Regulating ZNF217 via Sponging miR-361-3p in Alzheimer's Disease.","date":"2020","source":"Journal of Alzheimer's disease : JAD","url":"https://pubmed.ncbi.nlm.nih.gov/32741808","citation_count":55,"is_preprint":false},{"pmid":"30248538","id":"PMC_30248538","title":"Suppression of lncRNA-ATB prevents amyloid-β-induced neurotoxicity in PC12 cells via regulating miR-200/ZNF217 axis.","date":"2018","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/30248538","citation_count":52,"is_preprint":false},{"pmid":"26431164","id":"PMC_26431164","title":"The dark side of ZNF217, a key regulator of tumorigenesis with powerful biomarker value.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26431164","citation_count":51,"is_preprint":false},{"pmid":"25621839","id":"PMC_25621839","title":"MiR-203 suppresses ZNF217 upregulation in colorectal cancer and its oncogenicity.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25621839","citation_count":51,"is_preprint":false},{"pmid":"15476264","id":"PMC_15476264","title":"The candidate oncogene ZNF217 is frequently amplified in colon cancer.","date":"2004","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/15476264","citation_count":49,"is_preprint":false},{"pmid":"21483406","id":"PMC_21483406","title":"Overexpression of ZNF217 in glioblastoma contributes to the maintenance of glioma stem cells regulated by hypoxia-inducible factors.","date":"2011","source":"Laboratory investigation; a journal of technical methods and pathology","url":"https://pubmed.ncbi.nlm.nih.gov/21483406","citation_count":47,"is_preprint":false},{"pmid":"18625718","id":"PMC_18625718","title":"Genome analysis identifies the p15ink4b tumor suppressor as a direct target of the ZNF217/CoREST complex.","date":"2008","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/18625718","citation_count":47,"is_preprint":false},{"pmid":"21059223","id":"PMC_21059223","title":"ZNF217 confers resistance to the pro-apoptotic signals of paclitaxel and aberrant expression of Aurora-A in breast cancer cells.","date":"2010","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/21059223","citation_count":41,"is_preprint":false},{"pmid":"17266044","id":"PMC_17266044","title":"Multiple roles of the candidate oncogene ZNF217 in ovarian epithelial neoplastic progression.","date":"2007","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/17266044","citation_count":40,"is_preprint":false},{"pmid":"27267060","id":"PMC_27267060","title":"GATA3-driven expression of miR-503 inhibits prostate cancer progression by repressing ZNF217 expression.","date":"2016","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/27267060","citation_count":39,"is_preprint":false},{"pmid":"28207159","id":"PMC_28207159","title":"The critical role of the ZNF217 oncogene in promoting breast cancer metastasis to the bone.","date":"2017","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/28207159","citation_count":39,"is_preprint":false},{"pmid":"34403662","id":"PMC_34403662","title":"CircLPAR1/miR-212-3p/ZNF217 feedback loop promotes amyloid β-induced neuronal injury in Alzheimer's Disease.","date":"2021","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/34403662","citation_count":37,"is_preprint":false},{"pmid":"24973012","id":"PMC_24973012","title":"A functional interplay between ZNF217 and estrogen receptor alpha exists in luminal breast cancers.","date":"2014","source":"Molecular oncology","url":"https://pubmed.ncbi.nlm.nih.gov/24973012","citation_count":34,"is_preprint":false},{"pmid":"23436653","id":"PMC_23436653","title":"New insights into DNA recognition by zinc fingers revealed by structural analysis of the oncoprotein ZNF217.","date":"2013","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23436653","citation_count":33,"is_preprint":false},{"pmid":"32801903","id":"PMC_32801903","title":"OIP5-AS1/miR-137/ZNF217 Axis Promotes Malignant Behaviors in Epithelial Ovarian Cancer.","date":"2020","source":"Cancer management and research","url":"https://pubmed.ncbi.nlm.nih.gov/32801903","citation_count":32,"is_preprint":false},{"pmid":"30898548","id":"PMC_30898548","title":"The coordination between ZNF217 and LSD1 contributes to hepatocellular carcinoma progress and is negatively regulated by miR-101.","date":"2019","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/30898548","citation_count":31,"is_preprint":false},{"pmid":"21908891","id":"PMC_21908891","title":"The multi-zinc finger protein ZNF217 contacts DNA through a two-finger domain.","date":"2011","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21908891","citation_count":31,"is_preprint":false},{"pmid":"24962896","id":"PMC_24962896","title":"Global analysis of ZNF217 chromatin occupancy in the breast cancer cell genome reveals an association with ERalpha.","date":"2014","source":"BMC genomics","url":"https://pubmed.ncbi.nlm.nih.gov/24962896","citation_count":29,"is_preprint":false},{"pmid":"25281027","id":"PMC_25281027","title":"Chromosome 20q13.2 ZNF217 locus amplification correlates with decreased E-cadherin expression in ovarian clear cell carcinoma with PI3K-Akt pathway alterations.","date":"2014","source":"Human pathology","url":"https://pubmed.ncbi.nlm.nih.gov/25281027","citation_count":28,"is_preprint":false},{"pmid":"27519282","id":"PMC_27519282","title":"ZNF217/ZFP217 Meets Chromatin and RNA.","date":"2016","source":"Trends in biochemical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/27519282","citation_count":27,"is_preprint":false},{"pmid":"35121826","id":"PMC_35121826","title":"MicroRNA-135 inhibits initiation of epithelial-mesenchymal transition in breast cancer by targeting ZNF217 and promoting m6A modification of NANOG.","date":"2022","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/35121826","citation_count":26,"is_preprint":false},{"pmid":"37080415","id":"PMC_37080415","title":"FTO-stabilized miR-139-5p targets ZNF217 to suppress prostate cancer cell malignancies by inactivating the PI3K/Akt/mTOR signal pathway.","date":"2023","source":"Archives of biochemistry and biophysics","url":"https://pubmed.ncbi.nlm.nih.gov/37080415","citation_count":24,"is_preprint":false},{"pmid":"33426220","id":"PMC_33426220","title":"LncRNA MALAT1 promotes wound healing via regulating miR-141-3p/ZNF217 axis.","date":"2020","source":"Regenerative therapy","url":"https://pubmed.ncbi.nlm.nih.gov/33426220","citation_count":23,"is_preprint":false},{"pmid":"18661515","id":"PMC_18661515","title":"The eukaryotic translation elongation factor eEF1A2 induces neoplastic properties and mediates tumorigenic effects of ZNF217 in precursor cells of human ovarian carcinomas.","date":"2008","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/18661515","citation_count":23,"is_preprint":false},{"pmid":"25824781","id":"PMC_25824781","title":"ZNF217 is overexpressed and enhances cell migration and invasion in colorectal carcinoma.","date":"2015","source":"Asian Pacific journal of cancer prevention : APJCP","url":"https://pubmed.ncbi.nlm.nih.gov/25824781","citation_count":22,"is_preprint":false},{"pmid":"35668995","id":"PMC_35668995","title":"The PCOS GWAS Candidate Gene ZNF217 Influences Theca Cell Expression of DENND1A.V2, CYP17A1, and Androgen Production.","date":"2022","source":"Journal of the Endocrine Society","url":"https://pubmed.ncbi.nlm.nih.gov/35668995","citation_count":22,"is_preprint":false},{"pmid":"18425333","id":"PMC_18425333","title":"Silencing of ZNF217 gene influences the biological behavior of a human ovarian cancer cell line.","date":"2008","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/18425333","citation_count":22,"is_preprint":false},{"pmid":"27768596","id":"PMC_27768596","title":"Elevated expression of ZNF217 promotes prostate cancer growth by restraining ferroportin-conducted iron egress.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27768596","citation_count":21,"is_preprint":false},{"pmid":"32742190","id":"PMC_32742190","title":"Long non-coding RNA CTBP1-AS2 enhances cervical cancer progression via up-regulation of ZNF217 through sponging miR-3163.","date":"2020","source":"Cancer cell international","url":"https://pubmed.ncbi.nlm.nih.gov/32742190","citation_count":19,"is_preprint":false},{"pmid":"22843878","id":"PMC_22843878","title":"Gene amplification of ZNF217 located at chr20q13.2 is associated with lymph node metastasis in ovarian clear cell carcinoma.","date":"2012","source":"Anticancer research","url":"https://pubmed.ncbi.nlm.nih.gov/22843878","citation_count":18,"is_preprint":false},{"pmid":"15756435","id":"PMC_15756435","title":"Detection of Her2/neu, c-MYC and ZNF217 gene amplification during breast cancer progression using fluorescence in situ hybridization.","date":"2005","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/15756435","citation_count":17,"is_preprint":false},{"pmid":"34354851","id":"PMC_34354851","title":"ZNF217: the cerberus who fails to guard the gateway to lethal malignancy.","date":"2021","source":"American journal of cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/34354851","citation_count":13,"is_preprint":false},{"pmid":"38134973","id":"PMC_38134973","title":"ZNF217-activated Notch signaling mediates sulforaphane-suppressed stem cell properties in colorectal cancer.","date":"2023","source":"The Journal of nutritional biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/38134973","citation_count":13,"is_preprint":false},{"pmid":"32999043","id":"PMC_32999043","title":"Implication of ZNF217 in Accelerating Tumor Development and Therapeutically Targeting ZNF217-Induced PI3K-AKT Signaling for the Treatment of Metastatic Osteosarcoma.","date":"2020","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/32999043","citation_count":13,"is_preprint":false},{"pmid":"28607476","id":"PMC_28607476","title":"Zinc finger gene 217 (ZNF217) Promoted Ovarian Hyperstimulation Syndrome (OHSS) through Regulating E2 Synthesis and Inhibiting Thrombospondin-1 (TSP-1).","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28607476","citation_count":13,"is_preprint":false},{"pmid":"35809308","id":"PMC_35809308","title":"lncRNA PCAT1 might coordinate ZNF217 to promote CRC adhesion and invasion through regulating MTA2/MTA3/Snai1/E-cadherin signaling.","date":"2022","source":"Cellular and molecular biology (Noisy-le-Grand, France)","url":"https://pubmed.ncbi.nlm.nih.gov/35809308","citation_count":11,"is_preprint":false},{"pmid":"37648814","id":"PMC_37648814","title":"Frequent ZNF217 mutations lead to transcriptional deregulation of interferon signal transduction via altered chromatin accessibility in B cell lymphoma.","date":"2023","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/37648814","citation_count":11,"is_preprint":false},{"pmid":"31454071","id":"PMC_31454071","title":"A candidate pathogenic gene, zinc finger gene 217 (ZNF217), may contribute to polycystic ovary syndrome through prostaglandin E2.","date":"2019","source":"Acta obstetricia et gynecologica Scandinavica","url":"https://pubmed.ncbi.nlm.nih.gov/31454071","citation_count":10,"is_preprint":false},{"pmid":"36551531","id":"PMC_36551531","title":"The Intricate Interplay between the ZNF217 Oncogene and Epigenetic Processes Shapes Tumor Progression.","date":"2022","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/36551531","citation_count":9,"is_preprint":false},{"pmid":"38852653","id":"PMC_38852653","title":"Hsa_circ_0049472 contributed to amyloid-beta peptide-induced neurotoxicity, apoptosis and inflammation via regulating PI3K-AKT signaling pathway by interacting with miR-22-3p/ZNF217 axis.","date":"2024","source":"Brain research bulletin","url":"https://pubmed.ncbi.nlm.nih.gov/38852653","citation_count":9,"is_preprint":false},{"pmid":"20429623","id":"PMC_20429623","title":"CCND1 and ZNF217 gene amplification is equally frequent in BRCA1 and BRCA2 associated and non-BRCA breast cancer.","date":"2010","source":"Neoplasma","url":"https://pubmed.ncbi.nlm.nih.gov/20429623","citation_count":8,"is_preprint":false},{"pmid":"22966406","id":"PMC_22966406","title":"Coexistence of copy number increases of ZNF217 and CYP24A1 in colorectal cancers in a Chinese population.","date":"2010","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/22966406","citation_count":8,"is_preprint":false},{"pmid":"34234548","id":"PMC_34234548","title":"CircCSNK1G1 Contributes to the Tumorigenesis of Gastric Cancer by Sponging miR-758 and Regulating ZNF217 Expression.","date":"2021","source":"Cancer management and research","url":"https://pubmed.ncbi.nlm.nih.gov/34234548","citation_count":7,"is_preprint":false},{"pmid":"27792410","id":"PMC_27792410","title":"Regulation of expression of the p21CIP1 gene by the transcription factor ZNF217 and MDM2.","date":"2016","source":"Biochemistry and cell biology = Biochimie et biologie cellulaire","url":"https://pubmed.ncbi.nlm.nih.gov/27792410","citation_count":6,"is_preprint":false},{"pmid":"34277402","id":"PMC_34277402","title":"Exploring the Significance of the Exon 4-Skipping Isoform of the ZNF217 Oncogene in Breast Cancer.","date":"2021","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/34277402","citation_count":6,"is_preprint":false},{"pmid":"35987744","id":"PMC_35987744","title":"Long non-coding RNA HOXA11-AS contributes to the formation of keloid by relieving the inhibition of miR-182-5p on ZNF217.","date":"2022","source":"Burns : journal of the International Society for Burn Injuries","url":"https://pubmed.ncbi.nlm.nih.gov/35987744","citation_count":6,"is_preprint":false},{"pmid":"38259608","id":"PMC_38259608","title":"ZNF217: An Oncogenic Transcription Factor and Potential Therapeutic Target for Multiple Human Cancers.","date":"2024","source":"Cancer management and research","url":"https://pubmed.ncbi.nlm.nih.gov/38259608","citation_count":5,"is_preprint":false},{"pmid":"40093906","id":"PMC_40093906","title":"CRISPR screening reveals ZNF217 as a vulnerability in high-risk B-cell acute lymphoblastic leukemia.","date":"2025","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/40093906","citation_count":5,"is_preprint":false},{"pmid":"36356557","id":"PMC_36356557","title":"Hsa_circ_0069094 positively regulates the expression of oncogenic ZNF217 by competitively targeting miR-758-3p to promote the development of breast cancer.","date":"2022","source":"Reproductive biology","url":"https://pubmed.ncbi.nlm.nih.gov/36356557","citation_count":5,"is_preprint":false},{"pmid":"23375235","id":"PMC_23375235","title":"Learning the local Bayesian network structure around the ZNF217 oncogene in breast tumours.","date":"2013","source":"Computers in biology and medicine","url":"https://pubmed.ncbi.nlm.nih.gov/23375235","citation_count":5,"is_preprint":false},{"pmid":"15897688","id":"PMC_15897688","title":"Coexistence of copy number changes of different genes (INK4A, erbB-1, erbB-2, CMYC, CCND1 and ZNF217) in urothelial tumors.","date":"2005","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/15897688","citation_count":5,"is_preprint":false},{"pmid":"40083704","id":"PMC_40083704","title":"Core transcriptional regulatory circuitry molecule ZNF217 promotes AML cell proliferation by up-regulating MYB.","date":"2025","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/40083704","citation_count":4,"is_preprint":false},{"pmid":"31191299","id":"PMC_31191299","title":"The ZNF217 Biomarker Predicts Low- and High-Risk Oncotype DX® Recurrence Score in ER-Positive Invasive Breast Cancers.","date":"2019","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/31191299","citation_count":4,"is_preprint":false},{"pmid":"35528669","id":"PMC_35528669","title":"Retracted Article: Berberine alleviates amyloid beta-induced injury in Alzheimer's disease by miR-107/ZNF217.","date":"2019","source":"RSC advances","url":"https://pubmed.ncbi.nlm.nih.gov/35528669","citation_count":4,"is_preprint":false},{"pmid":"37477798","id":"PMC_37477798","title":"Dimethyl fumarate inhibits ZNF217 and can be beneficial in a subset of estrogen receptor positive breast cancers.","date":"2023","source":"Breast cancer research and treatment","url":"https://pubmed.ncbi.nlm.nih.gov/37477798","citation_count":3,"is_preprint":false},{"pmid":"39877093","id":"PMC_39877093","title":"The Histone Demethylase LSD1/ZNF217/CoREST Complex is a Major Restriction Factor of Epstein-Barr Virus Lytic Reactivation.","date":"2025","source":"Research square","url":"https://pubmed.ncbi.nlm.nih.gov/39877093","citation_count":3,"is_preprint":false},{"pmid":"26198954","id":"PMC_26198954","title":"[Lentivirus-mediated shRNA targeting ZNF217 suppresses cell growth, migration, and invasion of glioma cells in vitro].","date":"2015","source":"Nan fang yi ke da xue xue bao = Journal of Southern Medical University","url":"https://pubmed.ncbi.nlm.nih.gov/26198954","citation_count":3,"is_preprint":false},{"pmid":"37653011","id":"PMC_37653011","title":"[Impacts of LncRNA NORAD on the Proliferation, Apoptosis, and Chemosensitivity of Non-small Cell Lung Cancer Cells by Regulating ZNF217 through MiR-199a-3p].","date":"2023","source":"Zhongguo fei ai za zhi = Chinese journal of lung cancer","url":"https://pubmed.ncbi.nlm.nih.gov/37653011","citation_count":2,"is_preprint":false},{"pmid":"25729968","id":"PMC_25729968","title":"Effect of ZNF217 gene polymorphisms on colorectal cancer development in a Mexican population.","date":"2015","source":"Genetics and molecular research : GMR","url":"https://pubmed.ncbi.nlm.nih.gov/25729968","citation_count":2,"is_preprint":false},{"pmid":"41345234","id":"PMC_41345234","title":"ZNF217 promotes ovarian cancer progression by impacting multiple pivotal steps in the metastatic process.","date":"2025","source":"NPJ precision oncology","url":"https://pubmed.ncbi.nlm.nih.gov/41345234","citation_count":1,"is_preprint":false},{"pmid":"16793610","id":"PMC_16793610","title":"[Oncogene ZNF217 amplification on chromosome 20 q in ovarian serous cystadenocarcinoma and its clinical implications].","date":"2006","source":"Nan fang yi ke da xue xue bao = Journal of Southern Medical University","url":"https://pubmed.ncbi.nlm.nih.gov/16793610","citation_count":1,"is_preprint":false},{"pmid":"16149004","id":"PMC_16149004","title":"[Study on amplification of ZNF217 in primary gastric carcinoma].","date":"2005","source":"Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery","url":"https://pubmed.ncbi.nlm.nih.gov/16149004","citation_count":1,"is_preprint":false},{"pmid":"38505863","id":"PMC_38505863","title":"ZNF217 Gene Copy Number as a Marker of Response to Standard Therapy Drugs According to ERα Status in Breast Cancer.","date":"2024","source":"Breast cancer (Dove Medical Press)","url":"https://pubmed.ncbi.nlm.nih.gov/38505863","citation_count":0,"is_preprint":false},{"pmid":"40447129","id":"PMC_40447129","title":"Tumor suppressor FBXO11 drives ubiquitin proteasomal degradation of KIF2C to limit ovarian cancer progression and is transcriptionally repressed by ZNF217.","date":"2025","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/40447129","citation_count":0,"is_preprint":false},{"pmid":"39354204","id":"PMC_39354204","title":"ZNF217 Mediates Transcriptional Activation of GRHL3 to Regulate SLC22A31 and Promote Malignant Progression in Thyroid Cancer.","date":"2024","source":"Molecular biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/39354204","citation_count":0,"is_preprint":false},{"pmid":"42191952","id":"PMC_42191952","title":"UCMSC-derived exosomal circDLGAP4 enhances HFF-1 cell proliferation and migration by promoting ZNF217 promoter H3K27 acetylation.","date":"2026","source":"Molecular genetics and genomics : MGG","url":"https://pubmed.ncbi.nlm.nih.gov/42191952","citation_count":0,"is_preprint":false},{"pmid":"19403395","id":"PMC_19403395","title":"[Expression of ZNF217 in human ovarian cystadenocarcinoma and its clinical significance].","date":"2009","source":"Nan fang yi ke da xue xue bao = Journal of Southern Medical University","url":"https://pubmed.ncbi.nlm.nih.gov/19403395","citation_count":0,"is_preprint":false},{"pmid":"41749916","id":"PMC_41749916","title":"Chromatin Engagement and Transcriptional Activity of the ZNF217 Exon 4-Skipping Isoform Are Associated with Breast Cancer Aggressiveness and Bone Metastasis.","date":"2026","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/41749916","citation_count":0,"is_preprint":false},{"pmid":"23879995","id":"PMC_23879995","title":"[ZNF217 expression correlates with the biological behavior of human ovarian cancer cells].","date":"2013","source":"Zhonghua zhong liu za zhi [Chinese journal of oncology]","url":"https://pubmed.ncbi.nlm.nih.gov/23879995","citation_count":0,"is_preprint":false},{"pmid":"17160949","id":"PMC_17160949","title":"[ZNF217 gene was detected in ovarian serous cystadenocarcinoma by fluorescence in situ hybridization].","date":"2006","source":"Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/17160949","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.07.01.25330014","title":"Immune Cell-Based Transcriptomic Mendelian Randomization and Colocalization Study on Type 1 Diabetes","date":"2025-07-02","source":"bioRxiv","url":"https://doi.org/10.1101/2025.07.01.25330014","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.11.07.622542","title":"Disease-Linked Regulatory DNA Variants and Homeostatic Transcription Factors in Epidermis","date":"2024-11-11","source":"bioRxiv","url":"https://doi.org/10.1101/2024.11.07.622542","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":44176,"output_tokens":8282,"usd":0.128379,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":17890,"output_tokens":6055,"usd":0.120413,"stage2_stop_reason":"end_turn"},"total_usd":0.248792,"stage1_batch_id":"msgbatch_01UT1AahFPCAyn2uVweS7A9z","stage2_batch_id":"msgbatch_01HuKWtKNT4Pqj1bc8eEP5RV","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1998,\n      \"finding\": \"ZNF217 encodes Krüppel-like transcription factors (1,062 and 1,108 aa) with eight C2H2 zinc fingers and a proline-rich transcription activation domain, and localizes to the nucleus; it was identified by positional cloning of the 20q13.2 amplicon.\",\n      \"method\": \"Positional cloning, sequence analysis, expression analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — positional cloning with sequence analysis and expression characterization, single study but multiple methods\",\n      \"pmids\": [\"9671742\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"ZNF217 overexpression in finite-lifespan human mammary epithelial cells (HMECs) drives immortalization, allowing cells to overcome senescence and acquire telomerase activity, stable telomere length, and resistance to TGF-β growth inhibition.\",\n      \"method\": \"Retroviral transduction of ZNF217 into primary HMECs; telomerase activity assays; TGF-β sensitivity assays\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — four independent immortalization experiments with functional readouts (telomerase, TGF-β resistance), single lab but replicated internally with multiple orthogonal assays\",\n      \"pmids\": [\"11245413\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"ZNF217 localizes predominantly to the nucleus and attenuates apoptotic signals from telomere dysfunction and doxorubicin-induced DNA damage; silencing ZNF217 by siRNA restores doxorubicin sensitivity. ZNF217 also increases Akt phosphorylation, and PI3K/Akt pathway inhibition decreases ZNF217 protein levels.\",\n      \"method\": \"siRNA knockdown; ZNF217 overexpression; apoptosis assays; immunoblotting for p-Akt; subcellular fractionation/localization\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain- and loss-of-function with multiple orthogonal readouts (apoptosis, Akt phosphorylation, drug sensitivity) in a single focused study\",\n      \"pmids\": [\"16203743\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"ZNF217 is a transcriptional repressor whose purified complex (~6 proteins) contains CoREST, BHC110/LSD1, HDAC2, and CtBP1; the complex possesses histone deacetylase activity and H3K4-specific demethylase activity. ZNF217 binds a specific DNA consensus recognition sequence (CRS) present in the E-cadherin promoter and represses E-cadherin transcription in vivo.\",\n      \"method\": \"Affinity purification of ZNF217 complex; HDAC and H3K4 demethylase in vitro assays; CAST assay for DNA CRS; ChIP; siRNA knockdown with transient transfection reporter assays\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — complex purification with in vitro enzymatic assays and DNA-binding selection, validated by ChIP and functional reporter assays, multiple orthogonal methods\",\n      \"pmids\": [\"17130829\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"ZNF217 contacts CtBP via two distinct motifs: a canonical PXDLS motif and a novel RRT (Arg-Arg-Thr) motif. The crystal structure of CtBP bound to an RRTGAPPAL peptide shows the RRT motif contacts a surface crevice distinct from the PXDLS-binding cleft. Mutations preventing ZNF217–CtBP contact reduce ZNF217-mediated transcriptional repression.\",\n      \"method\": \"Crystal structure of CtBP–RRT peptide complex; mutagenesis; transcriptional reporter assays\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure with functional mutagenesis validation in transcriptional assays\",\n      \"pmids\": [\"16940172\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Genome-wide ChIP-chip analysis identified thousands of ZNF217 binding sites in tumor cell lines; many promoters co-bound by ZNF217 and CtBP2 are activated upon ZNF217 removal, confirming ZNF217 functions as a transcriptional repressor. ZNF217 targets are enriched in organ development genes, and ZNF217 is downregulated during retinoic acid-induced differentiation of NTera2 cells.\",\n      \"method\": \"ChIP-chip (chromatin immunoprecipitation with microarray); ZNF217 siRNA knockdown; gene expression profiling\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genome-wide ChIP-chip with functional follow-up by siRNA knockdown and expression profiling, multiple orthogonal methods\",\n      \"pmids\": [\"17259635\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"The p15ink4b tumor suppressor gene is a direct target of the ZNF217/CoREST complex; ZNF217 knockdown in MCF-7 cells dramatically increases p15ink4b expression with increases in H3K4 dimethylation at its promoter. TGF-β stimulation releases ZNF217 from the p15ink4b promoter and allows SMAD2 binding and gene activation.\",\n      \"method\": \"Genome-wide expression profiling combined with ChIP-DSL; siRNA knockdown; ChIP for histone marks; TGF-β stimulation assays\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — ChIP-DSL genome-wide approach plus targeted siRNA and histone mark analysis with multiple orthogonal methods in single focused study\",\n      \"pmids\": [\"18625718\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"ZNF217 overexpression in immortalized ovarian surface epithelial cells (IOSE) transcriptionally activates eEF1A2, and siRNA to eEF1A2 reverses both eEF1A2-driven and ZNF217-driven anchorage independence and apoptosis resistance, placing eEF1A2 downstream of ZNF217 in a neoplastic transformation pathway.\",\n      \"method\": \"Retroviral ZNF217 overexpression; siRNA knockdown of eEF1A2; array CGH; Affymetrix expression analysis; anchorage independence and apoptosis assays\",\n      \"journal\": \"International journal of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — epistasis established by siRNA rescue experiments with multiple phenotypic readouts, single lab\",\n      \"pmids\": [\"18661515\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"A ZNF217 nuclear complex purified by affinity chromatography contains Jarid1b/Plu-1, G9a, LSD1, CoREST, and CtBP1 (confirmed by co-IP); the complex exhibits H3K4me3 demethylase activity (co-fractionating with Jarid1b), H3K9 methyltransferase activity (via G9a), and H3K27 methylation activity; EZH2 is an additional ZNF217 binding partner confirmed by co-IP.\",\n      \"method\": \"Affinity chromatography; mass spectrometry; co-immunoprecipitation; in vitro histone methylation and demethylation assays; anion-exchange chromatography fractionation\",\n      \"journal\": \"Epigenetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — affinity purification plus mass spectrometry, confirmed by co-IP, with in vitro enzymatic activity assays; single lab but multiple orthogonal methods\",\n      \"pmids\": [\"19242095\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"ZNF217 activates ErbB3 expression in breast cancer cells; ZNF217 recruitment to the ErbB3 promoter is CtBP1/2-independent, and ZNF217 and CtBP1/2 have opposing roles at the ErbB3 promoter. ErbB3 upregulation is one mechanism by which ZNF217 augments PI3K/Akt signaling.\",\n      \"method\": \"Ectopic ZNF217 expression; siRNA knockdown; ChIP; correlation analysis across 50 breast cancer cell lines and 15 primary tumors\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP and gain/loss-of-function with expression correlation, single lab, multiple methods\",\n      \"pmids\": [\"20661224\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"ZNF217 overexpression in MDA-MB-231 cells confers resistance to paclitaxel through deregulation of Bcl-2 family protein balance in the intrinsic apoptotic pathway; ZNF217 overexpression also increases Aurora-A protein expression, and Aurora-A kinase inhibition reverses paclitaxel resistance.\",\n      \"method\": \"Stable ZNF217 overexpression; siRNA knockdown; apoptosis assays; Bcl-2 family immunoblotting; Aurora-A inhibitor treatment; xenograft assays\",\n      \"journal\": \"Molecular cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain- and loss-of-function with mechanistic (Bcl-2 family, Aurora-A) and pharmacological rescue, single lab\",\n      \"pmids\": [\"21059223\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"ZNF217 DNA-binding activity is mediated by a two-finger unit (zinc fingers 6 and 7); NMR analysis and mutagenesis define the DNA binding surface, and the E-cadherin promoter site is a suboptimal binding site. Multi-finger proteins with two-finger units represent a distinct subclass of DNA recognition motif.\",\n      \"method\": \"NMR analysis; fluorescence anisotropy titrations; mutagenesis; sequence analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — NMR structure plus mutagenesis and biophysical binding assays in a single rigorous study\",\n      \"pmids\": [\"21908891\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"The ZNF217/CoREST complex occupies the p15ink4b promoter together with DNMT3A; TGF-β treatment triggers active DNA demethylation by loss of ZNF217/CoREST/DNMT3A and recruitment of SMAD2/3, CBP, and TDG glycosylase. ZNF217 overexpression prevents TGF-β-dependent demethylation and p15ink4b expression by blocking SMAD2/3 and TDG recruitment; 5mC is converted to 5hmC prior to p15ink4b activation.\",\n      \"method\": \"ChIP and ChIP-seq; DNA immunoprecipitation for 5mC and 5hmC; TDG/MBD4 siRNA knockdown; ZNF217 overexpression; TGF-β stimulation\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — ChIP-seq plus functional demethylation assays, siRNA epistasis, and 5mC/5hmC IP in a rigorous multi-method study\",\n      \"pmids\": [\"22560925\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Crystal structure of a ZNF217 two-zinc-finger–DNA complex reveals that the side-chain interaction pattern differs substantially from the canonical ZF model and identifies two methyl-π interactions (tyrosine–thymine methyl) not previously described in classical ZF–DNA complexes.\",\n      \"method\": \"X-ray crystal structure determination of ZNF217 ZF6-7–DNA complex\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — crystal structure with detailed structural analysis, single study but Tier 1 method\",\n      \"pmids\": [\"23436653\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"ZNF217 and ERα proteins physically interact via the ERα hinge domain and the ZNF217 C-terminal domain (confirmed by co-IP in breast cancer cells and primary tumor samples); ZNF217 enhances ERα recruitment to estrogen response elements and ERα-dependent transcription of GREB1.\",\n      \"method\": \"Co-immunoprecipitation in cell lines and primary tumor samples; domain-mapping experiments; ChIP; transcriptional reporter assays\",\n      \"journal\": \"Molecular oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal co-IP in cells and tumors with ChIP and reporter assays, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"24973012\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Genome-wide ChIP-seq in MCF7 cells shows ZNF217 binding sites are enriched at distal regulatory regions marked by H3K27ac and H3K4me1, clustering with FOXA1, GATA3, and ERα binding sites; ERα co-precipitates ZNF217 and CtBP2 from nuclear extracts; ZNF217 depletion alters expression of genes co-bound by ZNF217 and ERα.\",\n      \"method\": \"ChIP-seq; co-immunoprecipitation; transcriptome profiling after ZNF217 siRNA depletion; bioinformatic motif enrichment analysis\",\n      \"journal\": \"BMC genomics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP-seq with co-IP and transcriptome profiling, single lab, multiple methods\",\n      \"pmids\": [\"24962896\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"ZNF217 inhibits m6A methylation of NANOG and KLF4 mRNAs under hypoxia in breast cancer cells, promoting BCSC specification; this ZNF217-dependent inhibition of m6A methylation is HIF-dependent and occurs independently of or in parallel with ALKBH5-mediated demethylation.\",\n      \"method\": \"ZNF217 knockdown; m6A quantification; HIF knockdown; pluripotency factor expression assays; in vivo metastasis assay\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — m6A quantification with siRNA epistasis (ZNF217, HIF knockdown) and in vivo validation, single lab\",\n      \"pmids\": [\"27590511\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"ZNF217 positively regulates E2 (estradiol) synthesis in granulosa cells by promoting CREB and thereby CYP19A1 (aromatase) expression; ZNF217 also negatively regulates TSP-1 expression, modulating vascular permeability through downstream claudin-1 and NO.\",\n      \"method\": \"In vitro KGN cell overexpression and knockdown of ZNF217; E2 assays; RT-qPCR for CYP19A1, CREB, TSP-1; vascular cell functional assays\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain- and loss-of-function in cell lines with multiple downstream readouts, single lab\",\n      \"pmids\": [\"28607476\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"ZNF217 interacts with MDM2; when co-expressed, ZNF217 and MDM2 form a complex and ZNF217 reduces acetylated p53 levels and suppresses p53-dependent p21 promoter activation, in part through recruitment of HDAC1.\",\n      \"method\": \"MDM2 affinity chromatography; mass spectrometry identification of ZNF217; co-expression in cancer cells; p53 acetylation immunoblotting; p21 promoter reporter assays\",\n      \"journal\": \"Biochemistry and cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — affinity chromatography/MS identification, co-expression functional assays, single lab, multiple methods\",\n      \"pmids\": [\"27792410\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"ZNF217 interacts with EZH2 to facilitate H3K27me3 at the ferroportin (FPN) promoter, repressing FPN transcription and retaining intracellular iron; MAZ transcription factor activates ZNF217 transcription and this axis regulates iron metabolism in prostate cancer cells.\",\n      \"method\": \"Co-immunoprecipitation of ZNF217 and EZH2; ChIP for H3K27me3 at FPN promoter; siRNA knockdown; overexpression assays; iron and cell growth assays\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP plus ChIP with functional iron metabolism readouts, single lab\",\n      \"pmids\": [\"27768596\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"ZNF217 overexpression in breast cancer cells activates the BMP signaling pathway, contributing to bone metastasis; BMP pathway inhibition (Noggin, LDN-193189) rescues ZNF217-dependent cell migration, invasion, and chemotaxis toward bone environment. ZNF217 increases metastatic growth rate and osteolytic lesions in vivo.\",\n      \"method\": \"Stable ZNF217 transfection; in vitro migration/invasion/chemotaxis assays; BMP inhibitor treatment; in vivo multimodal imaging in mouse models\",\n      \"journal\": \"The Journal of pathology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological and genetic epistasis with in vivo imaging, single lab, multiple methods\",\n      \"pmids\": [\"28207159\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"ZNF217 physically interacts with LSD1 in vivo and in vitro; ZNF217 knockdown increases H3K4me2 at the CDH1 (E-cadherin) promoter, indicating ZNF217 recruits LSD1 to epigenetically repress CDH1 transcription in hepatocellular carcinoma cells.\",\n      \"method\": \"Co-immunoprecipitation in vivo and in vitro; ChIP for H3K4me2; siRNA knockdown of ZNF217; expression analysis\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP plus ChIP with siRNA functional follow-up, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"30898548\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"ZNF217 mediates matrix stiffness- and collagen density-induced increases in Akt activity and mammary epithelial cell proliferation; ZNF217 is regulated by miR-203, which is repressed by matrix stiffness. In a mouse mammographic density model, reduced miR-203 correlates with higher Zfp217 (murine homolog) and elevated Akt activity.\",\n      \"method\": \"ZNF217 manipulation in culture; miR-203 profiling; Akt activity assays; mouse mammographic density model; quantitative proteomics and mechanical measurements of breast stroma\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple in vitro and in vivo methods with mechanistic epistasis (miR-203/ZNF217/Akt), single lab\",\n      \"pmids\": [\"32721948\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"ZNF217 forced expression in PCOS theca cells reduces androgen (DHEA) production, CYP17A1 mRNA, and DENND1A.V2 mRNA, while increasing miR-130b-3p levels; conversely, ZNF217 knockdown in normal theca cells increases DENND1A.V2 and CYP17A1 mRNA.\",\n      \"method\": \"ZNF217 overexpression in PCOS theca cells; shRNA lentiviral knockdown in normal theca cells; RT-qPCR for CYP17A1, DENND1A.V2, miR-130b-3p; androgen production assays\",\n      \"journal\": \"Journal of the Endocrine Society\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain- and loss-of-function with multiple downstream endocrine readouts, single lab\",\n      \"pmids\": [\"35668995\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"ZNF217 upregulates NANOG expression by reducing N6-methyladenosine (m6A) levels via interaction with METTL3; co-immunoprecipitation and methylated-RNA binding protein IP and PAR-CLIP assays confirmed ZNF217 interferes with METTL3-dependent m6A methylation of NANOG mRNA, promoting EMT in breast cancer.\",\n      \"method\": \"Co-immunoprecipitation; methylated-RNA immunoprecipitation; PAR-CLIP; dual-luciferase assay for miR-135/ZNF217 interaction; ZNF217 knockdown; xenograft assays\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP and MeRIP assays demonstrating m6A regulation mechanism, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"35121826\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"ZNF217 acts within a histone modifier complex containing LSD1, CoREST, and HDAC (confirmed by mass spectrometry), and knockout of ZNF217 in PMBCL cells changes chromatin accessibility at binding motifs for lymphoma-associated transcription factors, interfering with H3K4 methylation and H3K27 acetylation and altering expression of interferon-responsive genes.\",\n      \"method\": \"Targeted sequencing; ZNF217 knockout; mass spectrometry; gene expression profiling; ATAC-seq (chromatin accessibility); histone modification analysis\",\n      \"journal\": \"Leukemia\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — MS-confirmed complex plus chromatin accessibility (ATAC-seq) and histone modification analysis with KO functional follow-up, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"37648814\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"ZNF217 activates Notch1 transcription (confirmed by dual-luciferase reporter assay) to sustain cancer stem cell self-renewal and colorectal CSC marker expression; Notch1 knockdown rescues ZNF217-overexpression-driven stem cell properties.\",\n      \"method\": \"Dual-luciferase reporter assay; ZNF217 overexpression; Notch1 knockdown; CSC marker and sphere formation assays; in vivo xenograft\",\n      \"journal\": \"The Journal of nutritional biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reporter assay establishing direct transcriptional activation with epistasis by Notch1 KD, single lab\",\n      \"pmids\": [\"38134973\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Dimethyl fumarate (DMF) covalently modifies ZNF217 at cysteine residues (identified by cysteine-directed proteomics and confirmed with a DMF-chemical probe), inhibiting ZNF217 transcriptional activity on target genes and suppressing ZNF217-driven cancer phenotypes.\",\n      \"method\": \"Cysteine-directed activity-based proteomics; DMF-chemical probe confirmation; ZNF217 target gene expression analysis; gain/loss-of-function of ZNF217 combined with DMF treatment; xenograft assay\",\n      \"journal\": \"Breast cancer research and treatment\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — chemical proteomics identification confirmed by probe, with functional epistasis; single lab but two independent chemical methods\",\n      \"pmids\": [\"37477798\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"ZNF217 transcriptionally activates GRHL3 expression in thyroid cancer cells; GRHL3 in turn activates SLC22A31 transcription, forming a ZNF217/GRHL3/SLC22A31 axis promoting thyroid cancer cell malignancy; rescue overexpression of GRHL3 or SLC22A31 abrogates the effects of ZNF217 knockdown.\",\n      \"method\": \"Lentiviral knockdown of ZNF217, GRHL3, SLC22A31; RT-qPCR; bioinformatics differential expression; functional rescue assays\",\n      \"journal\": \"Molecular biotechnology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — epistasis by siRNA/shRNA rescue without direct promoter binding confirmation for ZNF217→GRHL3, single lab, single method type\",\n      \"pmids\": [\"39354204\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"ZNF217 is essential for B-ALL cell survival driven by MLL rearrangement or BCR-ABL; ZNF217 exerts oncogenic activity through both CoREST-dependent and CoREST-independent mechanisms; FOS is a direct downstream transcriptional target repressed by ZNF217 in a CoREST-independent manner (identified by integrated RNA-seq and CUT&RUN-seq).\",\n      \"method\": \"CRISPR-Cas9 screen; gain/loss-of-function assays; RNA-seq; CUT&RUN-seq; xenograft and PDX models\",\n      \"journal\": \"Theranostics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — CRISPR screen plus CUT&RUN-seq and RNA-seq mechanistic dissection with PDX model validation, single lab but multiple orthogonal genomic and functional methods\",\n      \"pmids\": [\"40093906\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"ZNF217 and LSD1 co-occupy the EBV immediate-early gene BZLF1 promoter and oriLyt enhancer regions; knockout of ZNF217 or LSD1, or CoREST triggers EBV lytic reactivation, and LSD1 depletion increases H3K4 methylation (but not H3K9me) at BZLF1 and oriLyt, inducing their long-range looping. ZNF217 thus functions as a restriction factor for EBV lytic reactivation within the LSD1/ZNF217/CoREST complex.\",\n      \"method\": \"Genome-wide CRISPR-Cas9 screen; ZNF217/LSD1/CoREST knockout; ChIP for H3K4me; 3D chromatin (looping) analysis; EBV reactivation assays; LSD1 small molecule antagonist; ganciclovir cytotoxicity assays; murine xenograft\",\n      \"journal\": \"Research square (preprint)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — CRISPR KO with ChIP and 3D chromatin assays in multiple cancer models; preprint with multiple methods but not yet peer-reviewed\",\n      \"pmids\": [\"39877093\"],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"ZNF217 promotes AML cell proliferation by directly activating MYB transcription; ZNF217 is part of the AML core transcriptional regulatory circuit (CRC) with ELF1, MEF2D, RUNX2, and FOXP1, sustaining super-enhancer activity through mutual auto-regulation loops. ZNF217 binding to MYB regulatory regions was confirmed by CUT&Tag.\",\n      \"method\": \"ChIP-seq analysis; CUT&Tag; shRNA knockdown; luciferase reporter assays; RNA-seq; in vitro and in vivo proliferation/viability assays\",\n      \"journal\": \"International journal of biological sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — CUT&Tag chromatin occupancy plus reporter assays and RNA-seq identifying MYB as direct target, single lab, multiple methods\",\n      \"pmids\": [\"40083704\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ZNF217 is a nuclear Krüppel-like C2H2 zinc-finger transcription factor that assembles a multi-subunit repressor complex containing LSD1/BHC110, CoREST, HDAC1/2, CtBP1/2, Jarid1b, G9a, and EZH2 to impose histone H3K4 demethylation, H3K9/H3K27 methylation, and histone deacetylation at target promoters; it binds DNA through a two-finger unit (ZF6–7) via a non-canonical interaction mode, represses tumor suppressors including p15ink4b, E-cadherin, and ferroportin, and also activates specific genes (ErbB3, Aurora-A, Notch1, MYB) in context-dependent, sometimes CtBP-independent manners; it further inhibits m6A methylation of pluripotency factor mRNAs by interfering with METTL3, interacts with ERα and MDM2 to modulate estrogen-responsive and p53-dependent transcription, and sustains cell survival partly through Akt/PI3K pathway activation, collectively driving immortalization, chemoresistance, EMT, metastasis, and cancer stem cell maintenance.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"ZNF217 is a Krüppel-like C2H2 zinc-finger transcription factor that nucleates a chromatin-modifying repressor complex to silence developmental and tumor-suppressor genes while driving cellular immortalization and oncogenic transformation [#0, #1, #3]. It recognizes DNA through a non-canonical two-finger unit (zinc fingers 6 and 7) whose side-chain contacts and tyrosine–thymine methyl-π interactions depart from the classical zinc-finger recognition mode [#11, #13]. Once bound, ZNF217 assembles a multi-subunit corepressor complex containing CoREST, LSD1/BHC110, HDAC1/2, and CtBP1/2 — engaging CtBP via both a canonical PXDLS motif and a novel RRT motif — and recruits additional histone modifiers Jarid1b, G9a, and EZH2 to impose H3K4 demethylation, H3K9/H3K27 methylation, and histone deacetylation at target promoters [#3, #4, #8, #21, #25]. Through this complex ZNF217 directly represses tumor suppressors including p15ink4b, E-cadherin (CDH1), and ferroportin, and at the p15ink4b promoter it cooperates with DNMT3A and antagonizes TGF-β-driven SMAD2/3 recruitment and active DNA demethylation [#3, #6, #12, #19, #21]. Beyond repression, ZNF217 activates context-specific targets — ErbB3, Aurora-A, Notch1, MYB, and FOS — sometimes in a CtBP- or CoREST-independent manner, augmenting PI3K/Akt signaling, conferring chemoresistance, and sustaining cancer stem-cell self-renewal [#2, #9, #10, #26, #29, #31]. ZNF217 additionally interacts with ERα to enhance estrogen-responsive transcription and with MDM2 to suppress p53-dependent transactivation, and it inhibits METTL3-dependent m6A methylation of pluripotency factor mRNAs (NANOG, KLF4) to promote EMT and breast cancer stem-cell specification [#14, #15, #18, #16, #24]. Collectively these activities drive immortalization, EMT, metastasis, and therapy resistance across multiple cancer types [#1, #20, #29].\",\n  \"teleology\": [\n    {\n      \"year\": 1998,\n      \"claim\": \"Establishing ZNF217's molecular identity was the first step: it answered whether the recurrently amplified 20q13.2 locus encoded a defined regulatory protein.\",\n      \"evidence\": \"Positional cloning and sequence/expression analysis of the 20q13.2 amplicon\",\n      \"pmids\": [\"9671742\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No DNA targets or interacting partners identified\", \"Activation vs repression function undefined\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Demonstrated that ZNF217 is functionally oncogenic, not merely amplified, by showing it immortalizes primary mammary epithelial cells.\",\n      \"evidence\": \"Retroviral ZNF217 transduction of HMECs with telomerase and TGF-β resistance readouts\",\n      \"pmids\": [\"11245413\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Transcriptional targets driving immortalization unknown\", \"Mechanism of TGF-β resistance unresolved\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Linked ZNF217 to survival signaling, showing it attenuates DNA-damage apoptosis and engages the PI3K/Akt axis, explaining a chemoresistance mechanism.\",\n      \"evidence\": \"siRNA knockdown and overexpression with apoptosis assays and p-Akt immunoblotting\",\n      \"pmids\": [\"16203743\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct mediators between ZNF217 and Akt not identified\", \"Reciprocal regulation of ZNF217 by Akt mechanistically unclear\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Defined ZNF217 as a sequence-specific corepressor by purifying its CoREST/LSD1/HDAC2/CtBP1 complex with H3K4 demethylase and deacetylase activity and identifying its DNA consensus, and resolved how it contacts CtBP.\",\n      \"evidence\": \"Affinity purification, in vitro enzymatic assays, CAST DNA selection, ChIP; plus CtBP–RRT peptide crystal structure with mutagenesis\",\n      \"pmids\": [\"17130829\", \"16940172\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full target gene repertoire unknown\", \"Structural basis of DNA recognition not yet determined\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Established the genome-wide scope of ZNF217 repression, showing it occupies thousands of developmental-gene promoters with CtBP2 and is downregulated during differentiation.\",\n      \"evidence\": \"ChIP-chip with siRNA knockdown and expression profiling in tumor lines and NTera2 cells\",\n      \"pmids\": [\"17259635\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct vs indirect targets not all distinguished\", \"Mechanism linking binding to activation upon removal unclear\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Connected ZNF217 to growth control by identifying p15ink4b as a direct CoREST-complex target whose TGF-β activation requires ZNF217 release, and placed eEF1A2 downstream in transformation.\",\n      \"evidence\": \"ChIP-DSL, histone-mark ChIP, TGF-β stimulation, and siRNA epistasis with eEF1A2\",\n      \"pmids\": [\"18625718\", \"18661515\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How TGF-β triggers ZNF217 eviction not defined\", \"eEF1A2 regulation mechanism (direct/indirect) unclear\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Expanded the corepressor complex to include Jarid1b, G9a, and EZH2, establishing that ZNF217 coordinates multiple histone-modifying activities (H3K4 demethylation, H3K9/H3K27 methylation).\",\n      \"evidence\": \"Affinity chromatography, mass spectrometry, co-IP, and in vitro histone methylation/demethylation assays\",\n      \"pmids\": [\"19242095\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry and assembly order of subunits unknown\", \"Whether all activities act at the same loci unresolved\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Showed ZNF217 also functions as a transcriptional activator at specific loci, activating ErbB3 (CtBP-independent) and Aurora-A to drive Akt signaling and paclitaxel resistance.\",\n      \"evidence\": \"ChIP, gain/loss-of-function, Bcl-2 family immunoblotting, Aurora-A inhibition, and xenografts\",\n      \"pmids\": [\"20661224\", \"21059223\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular switch between repression and activation unknown\", \"Direct vs indirect activation of Aurora-A unclear\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Resolved the DNA-recognition mechanism, defining a two-finger (ZF6-7) DNA-binding unit and a suboptimal E-cadherin site, establishing ZNF217 as a distinct recognition subclass.\",\n      \"evidence\": \"NMR analysis, fluorescence anisotropy, and mutagenesis\",\n      \"pmids\": [\"21908891\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Genome-wide consensus relationship to ZF6-7 specificity incomplete\", \"Role of remaining zinc fingers undefined\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Detailed the epigenetic mechanism at p15ink4b, showing the ZNF217/CoREST/DNMT3A complex blocks TGF-β-induced active DNA demethylation by preventing SMAD2/3 and TDG recruitment.\",\n      \"evidence\": \"ChIP-seq, 5mC/5hmC DNA-IP, TDG/MBD4 siRNA, and TGF-β stimulation\",\n      \"pmids\": [\"22560925\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Generality of DNMT3A coupling beyond p15ink4b unknown\", \"Signal triggering complex displacement not fully defined\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Provided atomic detail of ZNF217–DNA contacts, revealing non-canonical methyl-π (tyrosine–thymine) interactions absent from classical zinc-finger complexes.\",\n      \"evidence\": \"X-ray crystal structure of ZF6-7–DNA complex\",\n      \"pmids\": [\"23436653\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structure of full-length protein on chromatin unknown\", \"Link between recognition mode and target selection unresolved\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Integrated ZNF217 into estrogen signaling, showing direct ERα interaction and co-occupancy with FOXA1/GATA3/ERα at distal enhancers regulating estrogen-responsive genes.\",\n      \"evidence\": \"Co-IP in cells/tumors, domain mapping, ChIP-seq, and transcriptome profiling after depletion\",\n      \"pmids\": [\"24973012\", \"24962896\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether ERα coactivation is corepressor-complex-dependent unclear\", \"Single-lab co-IP for ERα–ZNF217 interaction\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Broadened ZNF217's regulatory range to RNA m6A, p53, and iron metabolism — inhibiting m6A of NANOG/KLF4 under hypoxia, interacting with MDM2 to suppress p53, and partnering with EZH2 to repress ferroportin.\",\n      \"evidence\": \"m6A quantification with HIF knockdown; MDM2 affinity-MS and p53/p21 assays; EZH2 co-IP and ferroportin ChIP\",\n      \"pmids\": [\"27590511\", \"27792410\", \"27768596\", \"28607476\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct vs indirect interference with m6A machinery undefined at this stage\", \"Physiological balance between these distinct activities unknown\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Confirmed in hepatocellular carcinoma that ZNF217 recruits LSD1 to the CDH1 promoter to enforce E-cadherin silencing via H3K4me2 removal.\",\n      \"evidence\": \"Co-IP in vivo/in vitro, H3K4me2 ChIP, and siRNA knockdown\",\n      \"pmids\": [\"30898548\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Cell-type generality of LSD1 recruitment to CDH1 unclear\", \"Direct ZNF217 binding to CDH1 promoter in this system not structurally validated\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Linked ZNF217 to mechanotransduction and metastatic niche signaling — matrix stiffness represses miR-203 to elevate ZNF217 and Akt activity, while ZNF217 activates BMP signaling to promote bone metastasis.\",\n      \"evidence\": \"miR-203 profiling, Akt assays, mouse mammographic density model; BMP inhibitor rescue and in vivo imaging\",\n      \"pmids\": [\"32721948\", \"28207159\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct ZNF217 targets in BMP/mechanotransduction pathways not mapped\", \"Single-lab in vivo findings\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Mechanistically resolved the m6A connection, showing ZNF217 physically interacts with METTL3 to block m6A methylation of NANOG mRNA and promote EMT.\",\n      \"evidence\": \"Co-IP, MeRIP, PAR-CLIP, dual-luciferase, knockdown, and xenografts\",\n      \"pmids\": [\"35121826\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether ZNF217 directly inhibits METTL3 catalysis or sequesters it unclear\", \"Breadth of m6A-regulated transcripts undefined\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Extended ZNF217's repressor function to chromatin accessibility in lymphoma and EBV restriction, and uncovered druggability through covalent cysteine modification by dimethyl fumarate.\",\n      \"evidence\": \"ATAC-seq and MS-confirmed complex in PMBCL; CRISPR-KO ChIP and 3D chromatin in EBV (preprint); cysteine-directed proteomics with DMF probe\",\n      \"pmids\": [\"37648814\", \"37477798\", \"39877093\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"EBV findings from preprint not peer-reviewed\", \"DMF target selectivity in cells not fully defined\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Established ZNF217 as a transcriptional activator of Notch1 sustaining colorectal cancer stem-cell self-renewal.\",\n      \"evidence\": \"Dual-luciferase reporter, overexpression, Notch1 knockdown rescue, and sphere/xenograft assays\",\n      \"pmids\": [\"38134973\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct promoter occupancy at Notch1 not confirmed by ChIP\", \"Relationship to corepressor complex unclear\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Proposed a ZNF217/GRHL3/SLC22A31 transcriptional axis driving thyroid cancer malignancy.\",\n      \"evidence\": \"Lentiviral knockdown and functional rescue without direct promoter-binding confirmation\",\n      \"pmids\": [\"39354204\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No direct ZNF217 binding to GRHL3 promoter demonstrated\", \"Single-lab, single-method-type epistasis\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Defined ZNF217 as essential in leukemia, dissecting CoREST-dependent and -independent oncogenic outputs (FOS repression, MYB activation within a core transcriptional circuit).\",\n      \"evidence\": \"CRISPR screen, RNA-seq, CUT&RUN/CUT&Tag, reporter assays, and PDX models in B-ALL and AML\",\n      \"pmids\": [\"40093906\", \"40083704\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanistic basis of CoREST-independent activity unresolved\", \"How a corepressor activates MYB/super-enhancers structurally unclear\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"It remains unresolved how ZNF217 switches between corepressor and coactivator functions at different loci and how its CoREST-independent oncogenic activities are mechanistically executed.\",\n      \"evidence\": \"No single study in the timeline reconciles the activation/repression duality at the molecular level\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structural or biochemical model for context-dependent activation\", \"Determinants of CoREST-dependent vs -independent function unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [3, 11, 13]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [3, 5, 6, 26, 29, 31]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [3, 8]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [4, 18, 24]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [0, 2, 8]},\n      {\"term_id\": \"GO:0000228\", \"supporting_discovery_ids\": [3, 6, 12, 25]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [3, 8, 12, 25]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [5, 6, 26, 29, 31]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [1, 20, 29]},\n      {\"term_id\": \"R-HSA-8953854\", \"supporting_discovery_ids\": [16, 24]}\n    ],\n    \"complexes\": [\n      \"ZNF217/CoREST/LSD1/HDAC/CtBP corepressor complex\"\n    ],\n    \"partners\": [\n      \"CtBP1\",\n      \"LSD1\",\n      \"CoREST\",\n      \"EZH2\",\n      \"ESR1\",\n      \"MDM2\",\n      \"METTL3\",\n      \"HDAC1\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}